Business Services
Medical
Biopharmaceutical
Apellis Pharmaceuticals
$19.369876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$19.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.46 (2.43%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell APLS and other stocks, options, ETFs, and crypto commission-free!
About
Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. Read More It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Crestwood, KY.
Employees
87
Headquarters
Crestwood, Kentucky
Founded
2009
Market Cap
1.09B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
358.20K
High Today
$19.63
Low Today
$18.71
Open Price
$18.88
Volume
101.57K
52 Week High
$32.00
52 Week Low
$11.45
Collections
Business Services
Medical
Biopharmaceutical
Health
Pharmaceutical
2017 IPO
US
North America
News
Markets InsiderMar 22
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM Mass., and CRESTWOOD, Ky., March 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on March 13, 2019, the Compensation Committee of the Board of Directors approved the grant of equity awards to a new employee, as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and mat...
Price Paid on Robinhood
9% Higher
Right Now
52 Week Low
$11.45
Average Price Paid
$17.78
52 Week High
$32.00
Earnings
-$0.69
-$0.60
-$0.52
-$0.43
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 29, After Hours